Literature DB >> 9301351

Enteral nutrition after bone marrow transplantation.

A Papadopoulou1, A MacDonald, M D Williams, P J Darbyshire, I W Booth.   

Abstract

Nutritional insult after bone marrow transplantation (BMT) is complex and its nutritional management challenging. Enteral nutrition is cheaper and easier to provide than parenteral nutrition, but its tolerance and effectiveness in reversing nutritional depletion after BMT is poorly defined. Nutritional status, wellbeing, and nutritional biochemistry were prospectively assessed in 21 children (mean age 7.5 years; 14 boys) who received nasogastric feeding after BMT (mean duration 17 days) and in eight children (mean age 8 years, four boys) who refused enteral nutrition and who received dietetic advice only. Enteral nutrition was stopped prematurely in eight patients. Greater changes in weight and mid upper arm circumference were observed in the enteral nutrition group, while positive correlations were found between the duration of feeds and increase in weight and in mid upper arm circumference. Vomiting and diarrhoea had a similar incidence in the two groups, while fever and positive blood cultures occurred more frequently in the dietetic advice group. Diarrhoea occurring during enteral nutrition was not associated with fat malabsorption, while carbohydrate malabsorption was associated with rotavirus infection only. Enteral feeding did not, however, affect bone marrow recovery, hospital stay, general wellbeing, or serum albumin concentrations. Hypomagnesaemia, hypophosphataemia, zinc and selenium deficiency were common in both groups. In conclusion, enteral nutrition, when tolerated, is effective in limiting nutritional insult after BMT. With existing regimens nutritional biochemistry should be closely monitored in order to provide supplements when required.

Entities:  

Mesh:

Year:  1997        PMID: 9301351      PMCID: PMC1717280          DOI: 10.1136/adc.77.2.131

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  42 in total

1.  Graft-versus-host disease of the intestine: a protein losing enteropathy characterized by fecal alpha 1-antitrypsin.

Authors:  S A Weisdorf; L M Salati; J A Longsdorf; N K Ramsay; H L Sharp
Journal:  Gastroenterology       Date:  1983-11       Impact factor: 22.682

2.  [Nutritional problems caused by anticancer treatment in children].

Authors:  P Goyens; J Otten
Journal:  Rev Med Brux       Date:  1983-04

3.  New norms of upper limb fat and muscle areas for assessment of nutritional status.

Authors:  A R Frisancho
Journal:  Am J Clin Nutr       Date:  1981-11       Impact factor: 7.045

4.  Continuous enteric alimentation with a blenderized formula in cancer cachexia.

Authors:  J B Block; R T Chlebowski; J N Herrold
Journal:  Clin Oncol       Date:  1981-06

5.  Total parenteral nutrition in bone marrow transplantation: a clinical evaluation.

Authors:  S Weisdorf; C Hofland; H L Sharp; K Teasley; K Schissel; P B McGlave; N Ramsay; J Kersey
Journal:  J Pediatr Gastroenterol Nutr       Date:  1984       Impact factor: 2.839

6.  Effectiveness of enteral and parenteral nutrition in the nutritional management of children with Wilms' tumors.

Authors:  K A Rickard; A Kirksey; R L Baehner; J L Grosfeld; A Provisor; R M Weetman; L A Boxer; T V Ballantine
Journal:  Am J Clin Nutr       Date:  1980-12       Impact factor: 7.045

7.  A study of the nutritional status of pediatric cancer patients.

Authors:  S S Donaldson; M N Wesley; W D DeWys; R M Suskind; N Jaffe; J vanEys
Journal:  Am J Dis Child       Date:  1981-12

8.  The effect of total parenteral nutrition on chemotherapy-induced myelosuppression. A randomized study.

Authors:  R C Shamberger; P A Pizzo; J T Goodgame; S F Lowry; M M Maher; R A Wesley; M F Brennan
Journal:  Am J Med       Date:  1983-01       Impact factor: 4.965

9.  Effect of total parenteral nutrition on marrow recovery during induction therapy for acute nonlymphocytic leukemia in childhood.

Authors:  D M Hays; R J Merritt; L White; J Ashley; S E Siegel
Journal:  Med Pediatr Oncol       Date:  1983

10.  A clinical trial of hyperalimentation in children with metastatic malignancies.

Authors:  J van Eys; E M Copeland; A Cangir; G Taylor; B Teitell-Cohen; P Carter; C Ortiz
Journal:  Med Pediatr Oncol       Date:  1980
View more
  5 in total

1.  The burden of chemotherapy-induced nausea and vomiting in children receiving hematopoietic stem cell transplantation conditioning: a prospective study.

Authors:  J Flank; J Sparavalo; H Vol; L Hagen; R Stuhler; D Chong; S Courtney; J J Doyle; A Gassas; T Schechter; L L Dupuis
Journal:  Bone Marrow Transplant       Date:  2017-06-05       Impact factor: 5.483

2.  Could enteral nutrition improve the outcome of patients with haematological malignancies undergoing allogeneic haematopoietic stem cell transplantation? A study protocol for a randomized controlled trial (the NEPHA study).

Authors:  Richard Lemal; Aurélie Cabrespine; Bruno Pereira; Cécile Combal; Aurélie Ravinet; Eric Hermet; Jacques-Olivier Bay; Corinne Bouteloup
Journal:  Trials       Date:  2015-04-07       Impact factor: 2.279

3.  Enteral nutrition protects children undergoing allogeneic hematopoietic stem cell transplantation from blood stream infections.

Authors:  Daniele Zama; Edoardo Muratore; Elena Biagi; Maria Luisa Forchielli; Roberto Rondelli; Marco Candela; Arcangelo Prete; Andrea Pession; Riccardo Masetti
Journal:  Nutr J       Date:  2020-04-10       Impact factor: 3.271

4.  [Requirements for hygiene in the medical care of immunocompromised patients. Recommendations from the Committee for Hospital Hygiene and Infection Prevention at the Robert Koch Institute (RKI)].

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2010-04       Impact factor: 1.513

Review 5.  Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview.

Authors:  N M Blijlevens; J P Donnelly; B E De Pauw
Journal:  Bone Marrow Transplant       Date:  2000-06       Impact factor: 5.483

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.